Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 5NIH 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Genitourinary 2

Conditions

Melanoma 3

Interventions

aldesleukin 69Cyclophosphamide 50fludarabine phosphate 36fludarabine 30Interleukin-2 27incomplete Freund's adjuvant 22Ipilimumab 20Biopsy 20Specimen Handling 19Magnetic Resonance Spectroscopy 19MART-1 Antigen 15CTLA-4 Antigen 15sargramostim 14Nivolumab 13Filgrastim 13montanide ISA 51 12Sorafenib 12Interferon-alpha 11pembrolizumab 10trametinib 9Temozolomide 9Bevacizumab 9dabrafenib 8temsirolimus 7Sirolimus 7Gene Expression Profiling 7tanespimycin 6Paclitaxel 6Dacarbazine 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Protein Subunit Vaccines × Dermatologic × Clear all
NCT00706992 2015-10-28

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
50 enrolled 13 charts
Dermatologic

Melanoma

NCT01989559 2015-01-26

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
Dermatologic

Melanoma

NCT00005949 2013-01-16

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡